New Advance in Central and Peripheral Circulation in Diabetes

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2086

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark
2. Department of Clinical Medicine and The August Krogh Institute, NEXS, Copenhagen University, Copenhagen, Denmark
Interests: magnetic resonance imaging; heart failure; diabetes; physiology; diastolic dysfunction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Even with modern treatments for hypercholesterolemia and hypertension, patients with diabetes still suffer from a significantly increased risk of heart failure (HF). Recent studies have documented that approximately 50% of patients with diabetes and HF suffer from HF with preserved ejection fraction (HFpEF). This prevalence is expected to increase in the near future. The precise mechanisms responsible for HFpEF in patients with DM, but also in elderly patients with hypertension and not necessarily diabetes, are still not well-elucidated. In diabetes, it has been conclusively shown that these patients (even before HFpEF has ensued) have increase myocardial fibrosis (in some cases even "islands of fibrosis"), left ventricle hypertrophy and significantly lowered maximally attainable myocardial blood flow. Focus has been on the hearts of patients with HFpEF, but it is increasingly acknowledged, that "a stiff peripheral circulation" may be at least partly to blame. Not only do patients with diabetes (and other variants of patients with HFpEF) often have hypertension and elevated total peripheral resistance, they often also have "stiff conductance arteries", which in itself probably increases the afterload for the left ventricle. Obviously conductance artery atheromatosis may be seen in diabetes, but patients with diabetes often also have conductance artery "media sclerosis" (previously known as Monckeberg medial calcific sclerosis).

This Special Issue in Diagnostics will focus on the peripheral circulation and its relation to cardiac function not only in patients with diabetes, but also other patient groups with increased risk of HFpEF. We will welcome all contributions, both reviews and original papers in this field, from animal models and from patient studies. 

Dr. Per Lav Madsen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • heart failure with preserved ejection fraction
  • heart failure
  • cardiac hypertrophy
  • non-invasive imaging

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 984 KiB  
Article
Post-Coronary Artery Bypass Grafting Outcomes of Patients with/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis
by Razan Al Namat, Letiția Doina Duceac, Liliana Chelaru, Marius Gabriel Dabija, Cristian Guțu, Constantin Marcu, Maria Valentina Popa, Florina Popa, Elena Roxana Bogdan Goroftei and Elena Țarcă
Diagnostics 2024, 14(1), 16; https://doi.org/10.3390/diagnostics14010016 - 21 Dec 2023
Cited by 5 | Viewed by 1434
Abstract
Introduction: Increasingly, SGLT2 inhibitors save patients with heart failure and comorbidities such as type-2 diabetes mellitus (T2DM) and chronic kidney disease (CKD); the inhibition of sodium-glucose cotransporter 2 (SGLT2) was first studied in patients with diabetes as a solution to lower glucose levels [...] Read more.
Introduction: Increasingly, SGLT2 inhibitors save patients with heart failure and comorbidities such as type-2 diabetes mellitus (T2DM) and chronic kidney disease (CKD); the inhibition of sodium-glucose cotransporter 2 (SGLT2) was first studied in patients with diabetes as a solution to lower glucose levels by preventing glucose reabsorption and facilitating its elimination; in the process, researchers took notice of how SGLT2 inhibitors also seemed to have beneficial cardiovascular effects in patients with both diabetes and cardiovascular disease. Aim: Our single-center prospective study assesses outcomes of post-coronary artery bypass grafting (CABG) rehabilitation and SLGT2 inhibition in CABG patients with/without T2DM and with/without CKD. Materials and Methods: One hundred twenty consecutive patients undergoing CABG were included in the analysis. Patients were divided into four subgroups: diabetes patients with chronic kidney disease (T2DM + CKD), diabetes patients without chronic kidney disease (T2DM−CKD), prediabetes patients with chronic kidney disease (PreD+CKD), and prediabetes patients without chronic kidney disease (PreD−CKD). Echocardiographic and laboratory investigations post-surgery (phase I) and 6 months later (phase II) included markers for cardiac ischemia, glycemic status, and renal function, and metabolic equivalents were investigated. Results: One hundred twenty patients participated, mostly men, overweight/obese, hypertensive, smokers; 65 had T2DM (18 with CKD), and 55 were prediabetic (17 with CKD). The mean ejection fraction increased by 8.43% overall but significantly more in the prediabetes group compared to the T2DM group (10.14% vs. 6.98%, p < 0.05). Overall, mean heart-type fatty-acid-binding protein (H-FABP) levels returned to normal levels, dropping from 68.40 ng/mL to 4.82 ng/mL (p = 0.000), and troponin data were more nuanced relative to an overall, strongly significant decrease of 44,458 ng/L (p = 0.000). Troponin levels in patients with CKD dropped more, both in the presence of T2DM (by 82,500 ng/L, p = 0.000) and in patients without T2DM (by 73,294 ng/L, p = 0.047). As expected, the overall glycated hemoglobin (HbA1c) levels improved significantly in those with prediabetes (from 6.54% to 5.55%, p = 0.000); on the other hand, the mean HbA1c changed from 7.06% to 6.06% (p = 0.000) in T2DM, and the presence or absence of CKD did not seem to make any difference: T2DM+CKD 7.01–6.08% (p = 0.000), T2DM−CKD 7.08–6.04% (p = 0.000), PreD+CKD 5.66–4.98% (p = 0.014), and PreD−CKD 6.03–4.94% (p = 0.00). Compared to an overall gain of 11.51, the GFRs of patients with CKD improved by 18.93 (68.15–87.07%, p = 0.000) in the presence of established diabetes and 14.89 (64.75–79.64%, p = 0.000) in the prediabetes group. Conclusions: Regarding the patients’ cardiac statuses, the results from our single-center analysis revealed a significant decrease in ischemic risk (H-FABP and hs-cTnI levels) with improvements in mean ejection fraction, glycemic status, and renal function in patients post-CABG with/without T2DM, with/without CKD, and with SGLT2 inhibitor dapagliflozin treatment while undergoing cardiac rehabilitation. Full article
(This article belongs to the Special Issue New Advance in Central and Peripheral Circulation in Diabetes)
Show Figures

Figure 1

Back to TopTop